SPARC — Sun Pharma Advanced Research Co Balance Sheet
0.000.00%
- IN₹41.99bn
- IN₹44.66bn
- IN₹717.66m
Annual balance sheet for Sun Pharma Advanced Research Co, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 157 | 157 | 4,066 | 1,571 | 19.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 385 | 519 | 439 | 1,060 | 187 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 598 | 712 | 4,550 | 2,694 | 262 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 951 | 951 | 1,073 | 1,086 | 993 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,297 | 2,801 | 8,301 | 5,150 | 3,355 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2,334 | 1,714 | 1,789 | 2,651 | 3,742 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 3,979 | 2,489 | 3,174 | 3,893 | 5,525 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -1,683 | 312 | 5,128 | 1,258 | -2,169 |
| Total Liabilities & Shareholders' Equity | 2,297 | 2,801 | 8,301 | 5,150 | 3,355 |
| Total Common Shares Outstanding |